The acute bronchiolitis rebound in children after COVID-19 restrictions: a retrospective, observational analysis.
Journal
Acta bio-medica : Atenei Parmensis
ISSN: 2531-6745
Titre abrégé: Acta Biomed
Pays: Italy
ID NLM: 101295064
Informations de publication
Date de publication:
13 02 2023
13 02 2023
Historique:
received:
07
08
2022
accepted:
13
09
2022
entrez:
14
2
2023
pubmed:
15
2
2023
medline:
16
2
2023
Statut:
epublish
Résumé
Bronchiolitis represents the main cause of illness and hospitalization in infants and young children. The aim of this study was to compare the Pediatric Emergency Department (PED) admissions for bronchiolitis during the post-COVID (Coronavirus disease) period to those of previous seasons and to analyze their etiology during COVID and post-COVID period. We compared demographics, clinical and microbiological data of children admitted to PED with bronchiolitis between September 2021 and March 2022 (post-COVID period) to the previous seasons (COVID and pre-COVID period). During the post-COVID period the bronchiolitis season started earlier than usual, with a peak reached in November 2021; a gradual reduction was subsequently observed between December 2021 and January 2022. Our data showed a prevalence of High Priority code in children admitted to the PED with bronchiolitis during the post-COVID period (61.4%) compared the pre-COVID period (34.8%) (p=0.00). Also regarding the hospitalization of these patients, we found a major rate of hospitalization during this epidemic season (p=0.035). In addition, only 4 (1.5%) of the tested children resulted positive for SARS-CoV-2 and all of them were admitted to PED during the post-COVID period. The search for the other respiratory viruses showed during the current season a prevalence of respiratory syncytial virus (RSV) (60.2%), followed by Human Rhinovirus (30.1%). The post-COVID period was characterized by an early and short-term peak in acute bronchiolitis, with an increased rate of hospitalization. In addition, SARS-CoV-2 infection was rarely cause of bronchiolitis in children under 2 years old.
Sections du résumé
BACKGROUND AND AIM
Bronchiolitis represents the main cause of illness and hospitalization in infants and young children. The aim of this study was to compare the Pediatric Emergency Department (PED) admissions for bronchiolitis during the post-COVID (Coronavirus disease) period to those of previous seasons and to analyze their etiology during COVID and post-COVID period.
METHODS
We compared demographics, clinical and microbiological data of children admitted to PED with bronchiolitis between September 2021 and March 2022 (post-COVID period) to the previous seasons (COVID and pre-COVID period).
RESULTS
During the post-COVID period the bronchiolitis season started earlier than usual, with a peak reached in November 2021; a gradual reduction was subsequently observed between December 2021 and January 2022. Our data showed a prevalence of High Priority code in children admitted to the PED with bronchiolitis during the post-COVID period (61.4%) compared the pre-COVID period (34.8%) (p=0.00). Also regarding the hospitalization of these patients, we found a major rate of hospitalization during this epidemic season (p=0.035). In addition, only 4 (1.5%) of the tested children resulted positive for SARS-CoV-2 and all of them were admitted to PED during the post-COVID period. The search for the other respiratory viruses showed during the current season a prevalence of respiratory syncytial virus (RSV) (60.2%), followed by Human Rhinovirus (30.1%).
CONCLUSIONS
The post-COVID period was characterized by an early and short-term peak in acute bronchiolitis, with an increased rate of hospitalization. In addition, SARS-CoV-2 infection was rarely cause of bronchiolitis in children under 2 years old.
Identifiants
pubmed: 36786263
doi: 10.23750/abm.v94i1.13552
pmc: PMC9987502
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2023031Références
Rev Med Virol. 2020 Jul;30(4):e2111
pubmed: 32431085
Lancet Public Health. 2020 May;5(5):e279-e288
pubmed: 32311320
Clin Microbiol Rev. 2010 Jan;23(1):74-98
pubmed: 20065326
Influenza Other Respir Viruses. 2017 Mar;11(2):122-129
pubmed: 28058797
Pediatrics. 2014 Nov;134(5):e1474-502
pubmed: 25349312
Eur J Pediatr. 2021 Jun;180(6):1969-1973
pubmed: 33517482
PLoS Comput Biol. 2016 Oct 7;12(10):e1005133
pubmed: 27716828
Ital J Pediatr. 2021 Oct 2;47(1):198
pubmed: 34600591
Pediatr Pulmonol. 2021 Dec;56(12):3669-3673
pubmed: 34473914
Pediatr Infect Dis J. 2013 Sep;32(9):950-5
pubmed: 23694832
Acta Paediatr. 2021 Apr;110(4):1297-1299
pubmed: 33506533
J Infect. 2021 Jan;82(1):1-35
pubmed: 33278399
Proc Natl Acad Sci U S A. 2020 Dec 1;117(48):30547-30553
pubmed: 33168723
Am J Emerg Med. 2021 May;43:115-117
pubmed: 33556796
Pediatr Pulmonol. 2021 Aug;56(8):2484-2488
pubmed: 33961732
Infect Dis Now. 2021 Aug;51(5):418-423
pubmed: 33991720
J Clin Virol. 2013 Aug;57(4):343-50
pubmed: 23684816
Nat Med. 2020 May;26(5):676-680
pubmed: 32371934
Front Pediatr. 2021 Jan 18;8:594898
pubmed: 33537260
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664
Arch Dis Child. 2022 Jun 15;:
pubmed: 35705371
Lancet. 2010 May 1;375(9725):1545-55
pubmed: 20399493